Hong Kong, October 20th / PRNewswire / -- GIX Internet Ltd. (Nasdaq ticker: GIXI; Tel Aviv Stock Exchange ticker: GIX) (hereinafter referred to as “GIX” or “the Company”) is an Israeli dual-listed technology company that focuses on “Physical AI”: applying intelligence to robots, people, and goods to make their movement more reliable and efficient in real operational environments. The Company develops a AI scheduling platform through its wholly-owned subsidiary Deliverz.AI, aimed at managing the flow of robots, people, and goods within operational premises. The Company believes that its commercial deployment in Sheba Medical Center forms the operational foundation of this strategy.

The platform is designed as a central operating system. It can allocate tasks in real-time based on location, priority, and availability, and manage mobility through a single interface. Its features include workload forecasting, resource planning, and route optimization, aimed at providing operators with visibility and the ability to adjust priorities and allocate resources to handle urgent tasks. The platform can also coordinate between robots and human employees, is compatible with robots from different suppliers, and integrates with existing facilities such as elevators, access control systems, turnstiles, and operational systems. This architecture is designed to allow customers to extend their workflows through a unified orchestration layer and to connect with compatible robot suppliers. The company provides solutions in the form of software and robots as a service.

The clearest commercial case is seen at Israel’s largest hospital Sheba Medical Center, which has been rated by Newsweek as one of the top 10 hospitals in the world. Deliverz.AI has been in commercial operation at this hospital since December 2025. According to company data, in its first main use case (transporting chemotherapy drugs from the pharmacy to the treatment units), the system reduced the average delivery time from about 40 minutes to about 14 minutes within 11 months, a decrease of approximately 65%. As of October 2026, the company reported that it had completed over 9,000 autonomous tasks, covering both indoor and outdoor routes.

In October 2026, this deployment was extended to more workflows: transporting bone marrow specimens from the hematology department to the laboratory, as well as transporting donated blood from blood collection centers to the blood bank. These expanded workflows further enhanced the platform's role across various departments. The company plans to add more drug and specimen transportation routes in this hospital, but cannot guarantee that this will definitely be achieved. The platform was selected through a public bidding process that allowed for the deployment of up to 30 robots; currently, 3 robots have been deployed. Sheba

The strategic goal of GIX is to go beyond the medical field and create a unified intelligent management system to coordinate robots, personnel, and other autonomous systems in complex operational environments. Hospitals represent the company's first commercial application scenario. The company believes that this platform could potentially be applied in fields such as manufacturing, logistics, pharmaceuticals, semiconductor facilities, aerospace, and automotive operations in the future, but no commercial deployments have yet been made in these industries.

The growth strategy of GIX includes: expanding work processes at existing locations, securing more commercial deployments, especially in the United States, and extending its orchestration software to other industries. The company's business model combines software with robotics services, and it believes that as customers broaden the scope of use for the platform, this model may lead to recurring revenue opportunities. The company's longer-term goal is to make Deliverz.AI the operational layer for robot, personnel, and cargo movement within customer premises, with medical scenarios laying the foundation for this expansion.

Contact Information:

Pulse Equity

Paid Promotion Disclosure

This article constitutes paid promotional content. GIX Internet Ltd. We have hired Pulse Equity (a brand/department of MR Solutions Limited) to provide investor awareness and promotion services, including the writing and dissemination of this article, and we have paid or will pay fees for such services.

GIX Internet Ltd. I have reviewed and approved the content of this article, but I do not control how, when, or to whom Pulse Equity distributes this information.

This article is for informational purposes only and does not constitute an offer to sell or a solicitation to purchase any securities of GIX Internet Ltd. Investing in the securities of GIX Internet Ltd involves significant risks. It is recommended that readers consult the documents submitted to the U.S. Securities and Exchange Commission and the Israel Securities Authority before making any investment decisions. The relevant documents can be obtained at www.sec.gov and www.magna.isa.gov.il respectively.

Forward-looking Statements

This article contains “forward-looking statements” in the context of the 1995 Private Securities Litigation Reform Act and other securities laws. The forward-looking statements in this article include: descriptions of the potential benefits, capabilities, and applications of Rail Vision technology; its potential role in railway safety, automation, and automated train operations; the possible expansion of the relationship between Rail Vision and Railserve and the likelihood of reaching a final agreement; as well as the possibility that existing integration and pilot projects may be transformed into larger-scale commercial contracts. These forward-looking statements are subject to risks and uncertainties, and actual results may differ significantly from those expressed or implied. For information regarding the risks and uncertainties that affect Gix Internet, please refer to the reports submitted by Gix Internet to the U.S. Securities and Exchange Commission (“SEC”). This includes, but is not limited to, the risks disclosed in the Form Form 20-F registration statement (file number 001-43362) submitted by the company to the SEC on June 18, 2026, and subsequent documents submitted to the SEC. Forward-looking statements are only valid as of the date they are made.

Pulse Equity Disclaimer

This article is produced by Pulse Equity (a brand/department of MR Solutions Limited (Hong Kong)) and is intended for general information and promotional purposes only. The content of this article does not constitute investment advice, financial advice, or medical advice, nor does it constitute a recommendation to buy, sell, or hold any securities; nor does it constitute an offer or solicitation in any jurisdiction. Pulse Equity is not a registered brokerage dealer, investment advisor, securities analyst, or medical professional. The information in this article is based on publicly available sources and statements that were considered reliable at the time of publication; however, Pulse Equity makes no representations or warranties regarding the accuracy or completeness of the information, nor has Pulse Equity independently verified all of the data cited.

This article is sponsored by the aforementioned company, which has paid for its production; this may constitute a conflict of interest.

It is recommended that readers conduct their own independent research and consult qualified financial, legal, medical, or other professional advisors before making any investment or health-related decisions.

The forward-looking statements cited in this article are subject to risks and uncertainties, and actual results may vary significantly. Past performance does not represent future results.

For complete disclosure, risk factors, and forward-looking statements, please visit: